Building Durability in Rare Disease Care With PANTHERx Rare

Advertisement
Feature|Videos|July 7, 2026

Building Durability in Rare Disease Care With PANTHERx Rare

Author(s)Bansi Nagji, CEO, PANTHERx Rare

Key Takeaways

Understand why scientific innovation targets rare and orphan disease treatments
Learn what distinguishes a rare-only pharmacy model from traditional specialty pharmacy approaches
Recognize why launch is only the starting point for long-term therapy success

Bansi Nagji discusses the shifting science behind rare and orphan drug development, including what it takes for therapies to succeed well beyond launch

Bansi Nagji, CEO of PANTHERx Rare, explores how innovation is increasingly directed toward rare and orphan diseases, driven by targeted incentives, tax breaks, and a more streamlined FDA approval pathway. Nagji covers the operational realities that set rare disease therapies apart, including cold chain logistics, weight-based titration regimens, and the intensive patient interactions required before a single prescription is even filled. Learn why launch marks the beginning of a therapy’s journey rather than its conclusion, and why ongoing work is necessary for payer access and long-term adherence.

What's Hot

Fundraisers swim 1,000 lengths to reopen pool

Scottie Scheffler played BMW Championship with hand, foot and mouth disease

Bobby Maximus Says Men Over 40 Are Making Fitness Too Complicated

Building Durability in Rare Disease Care With PANTHERx Rare

Scottie Scheffler played BMW Championship with hand, foot and mouth disease

Centers for Disease Control: Vaccination rates down for isle kindergartners

Scottie Scheffler battles through hand, foot and mouth disease to finish 7 under at BMW

Fundraisers swim 1,000 lengths to reopen pool

Scottie Scheffler played BMW Championship with hand, foot and mouth disease

Bobby Maximus Says Men Over 40 Are Making Fitness Too Complicated

The SharkNinja gadgets that are helping athletes push their fitness limits while hitting their nutrition goals

Opinion: The FDA must put biotech at its center or continue to cede early research to China

Inside Elevance’s digital chronic disease management strategy

Best, Worst States For Well

What do the Middle Ages tell us about mental health then and now? VCU historian Leigh Ann Craig has answers

Fitness

Fundraisers swim 1,000 lengths to reopen pool

Scottie Scheffler played BMW Championship with hand, foot and mouth disease

Bobby Maximus Says Men Over 40 Are Making Fitness Too Complicated

Health

Opinion: The FDA must put biotech at its center or continue to cede early research to China

Inside Elevance’s digital chronic disease management strategy

Best, Worst States For Well

Subscribe to Updates

What's Hot

Building Durability in Rare Disease Care With PANTHERx Rare

Building Durability in Rare Disease Care With PANTHERx Rare

Key Takeaways

Related Content

A Biopharma Perspective on What’s Next in Access & Affordability

Hospital Pharmacy and Supply Chain Leaders Want to Be Heard: Are you Ready to Listen?

From Launch to Loss of Exclusivity- Reducing Access and Affordability Barriers Across the Brand Lifecycle

Smarter, Faster, Bolder: AI’s New Role in Pharma Strategy

Rethinking Go-to-Market Strategy with Innovation in a Patient-Centric Era

Trending on Pharmaceutical Commerce

What Trutakna’s Approval Means for Specialty Launches

The Evolution and Impact of Patient Support Services: A Strategic Framework

How Real-Time DTP Data Are Rewriting Pharma’s Commercial Playbook

What Makes Patient Support Programs Work, and What Doesn’t

Building Durability in Rare Disease Care With PANTHERx Rare

Related Posts